A. **Federal Reserve Bank of Richmond** (Lloyd W. Bostian, Jr., Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *David B. Lilly, Jr.*, Middleburg, Virginia; to acquire up to 18.3 percent of the voting shares of Harvest Bancorp, Inc., Hamilton, Virginia, and thereby indirectly acquire The Farmers & Merchants National Bank of Hamilton, Hamilton, Virginia.

B. **Federal Reserve Bank of Chicago** (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *A. Andrew Boemi* and Flora Boemi; Andrew A. Boemi and Pamela L. Boemi; and Edwin Cee Buchanan and Marcia Buchanan; to acquire 13.98 percent of the voting shares of Madison Financial Corporation, Chicago, Illinois, and thereby indirectly acquire Madison Bank and Trust Company, Chicago, Illinois; Madison National Bank of Niles, Des Plaines, Illinois; and 1st National Bank of Wheeling, Wheeling, Illinois.

C. **Federal Reserve Bank of Minneapolis** (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Thomas J. Sexton*, St. Paul, Minnesota, to acquire 30 percent; Dennis J. Zaun, St. Cloud, Minnesota, to acquire 30 percent; James H. Lehr, Ottertail, Minnesota, to acquire 20 percent; and Gary Davis, Wadena, Minnesota, to acquire 20 percent of the voting shares of Yellow Medicine Bancshares Inc., Granite Falls, Minnesota, and thereby indirectly acquire Yellow Medicine County Bank, Granite Falls, Minnesota.

D. **Federal Reserve Bank of Kansas City** (Thomas M. Hoenig, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Russell Moore*, Albuquerque, New Mexico, as trustee for Banco de Vizcaya, Bilbao, Spain; to acquire 42 percent of the voting shares of New Mexico Banquest Investors Corporation, Santa Fe, New Mexico, and thereby indirectly acquire New Mexico Banquest Corporation, Santa Fe, New Mexico, and thereby indirectly acquire Banquest National Bank, Albuquerque, New Mexico; The First National Bank of Santa Fe, Santa Fe, New Mexico; and Banquest/First State Bank of Taos, Taos, New Mexico.

Board of Governors of the Federal Reserve System, July 15, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-16374 Filed 7-20-88; 8:45 am]

BILLING CODE 6210-01-M

Alan S. Fellheimer, et al; Change in Bank Control; Acquisitions of Shares of Banks or Bank Holding Companies; Collection

This notice corrects a previous **Federal Register** notice (FR Doc. 88-15424) published at page 26116 of the issue for Monday, July 11, 1988.

Under the Federal Reserve Bank of Cleveland, the first entry, for Equimark Corporation, is revised to include the following individual as an acquiring party:

James M. Murphy, Bethel Park, Pennsylvania.

Comments on this application must be received by July 26, 1988.

Board of Governors of the Federal Reserve System, July 15, 1988.

James McAffee,

Associate Secretary of the Board.

[FR Doc. 88-16377 Filed 7-20-88; 8:45 am]

BILLING CODE 6210-01-M

Regency Bancorporation; Acquisition of Company Engaged in Permissible Nonbanking Activities

The organization listed in this notice has applied under § 225.23 (a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23 (a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 11, 1988.

A. **Federal Reserve Bank of Kansas City** (Thomas M. Hoening, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. *Regency Bancorporation*, to acquire the credit related insurance agency activity now conducted by it subsidiary bank, Pueblo Boulevard Bank, Pueblo, Colorado, and thereby engage in the sale of credit related life, accident and health insurance pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 15, 1988.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 88-16375 Filed 7-20-88; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health; Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 53 FR 4458, February 16, 1988) is amended to reflect the following changes in the Office of Director, NIH: (1) Revise the functional statements for the Office of Administration (HNA7) and the Office of Research Services (HNAA); and (2) transfer the Division of Procurement (HNAA6) and the Division of Logistics (HNAA7) from the Office of Research Services (HNAA) to the Office of Administration (HNA7). The transfer of these two divisions will centralize the business functions of the NIH under the Associate Director for Administration.

Section HN-B, Organization and Functions is amended as follows: (1) Under the heading *Office of Administration (HNA7)*, delete the functional statement in its entirety and substitute the following:

Office of Administration (HNA7), (1) Advises the Director, NIH, and staff on administration and management; (2)

provides leadership and guidance on all phases of administrative management; and (3) directs staff and service functions in the areas of budget and financial management, personnel management, management policy, grant and contract management, management survey and review, procurement, and logistics.

(2) After the statement of the *Division of Personnel Management (HNA73)*, under the heading *Office of Administration (HNA7)*, insert the following:

Division of Procurement (HNA74). (1) Is responsible for all aspects of station support and intramural procurement; (2) manages the program using small purchases, formal advertisement, and negotiated contracting procedures; (3) provides technical assistance in specification preparation and in Small and Disadvantaged Business opportunities; (4) provides for follow-up on orders and for continuing contract administration; (5) formulates and disseminates policies and procedures to implement Federal and Departmental regulations (meeting needs for guidance in the procurement function); and (6) provides oversight and technical assistance (manuals and training guides) to decentralize station support procurement operations.

Divisions of Logistics (HNA75). (1) Plans and operates a centalized NIH-wide supply system providing a variety of needed chemical and other scientific and medical requirements; (2) provides transport services both in connection with the central supply system and the self-service stores as well as support of all campus activities; and (3) manages a personal property program (which accounts for and effectively utilizes government property used at the NIH).

(4) Under the heading *Office of Research Services (HNAA)*, delete the functional statement in its entirety and substitute the following:

Office of Research Services (HNAA). (1) Advises the Director, NIH, and staff on the management and provision of technical and administrative services to all components of NIH in support of the research mission; (2) plans and directs service programs for engineering services, safety, and space management, and technical services.

(5) Under the heading of *Office of Research Services (HNAA)*, delete the statements for the *Division of Procurement (HNAA6)* and the *Division of Logistics (HNAA7)* in their entirety.

Date: July 13, 1988.

Otis R. Bowen,

Secretary of Health and Human Services.

[FR Doc. 88-16418 Filed 7-20-88; 8:45 am]

BILLING CODE 4140-01-M

Office of the Secretary

Advisory Commission Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following national advisory body scheduled to meet during the month of August 1988:

Name: Secretary's Commission on Nursing

Date: August 4, 1988

Time: 8:30 a.m.

Place: Room 727A, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201

Purpose: The Secretary's Commission on Nursing will advise the Secretary of Health and Human Services on how the public and private sectors can work together to address problems and implement solutions regarding the supply of active registered nurses. The Commission will also consider the recruitment and retention of nurses in the U.S. Public Health Service, the Veteran's Administration and the Department of Defense. As appropriate for its work, the Commission will consider the findings of studies which are relevant to the development of a multi-year action plan for implementation by the public and private sectors.

Agenda: The agenda for the August 4 meeting will consist of discussions about potential recommendations for inclusion in the Commission's final report.

Agenda items are subject to change as priorities dictate.

Anyone wishing to attend these meetings who is hearing impaired and requires the services of an interpreter for the deaf should contact the Commission at least one week before the scheduled meeting. All such requests, as well as requests for information, should be addressed to the Secretary's Commission on Nursing, Hubert H. Humphrey Building, Room 600E, 200 Independence Avenue, SW., Washington, DC 20201, telephone 202/245-0409.

John Busa,

Administrative Officer, Secretary's Commission on Nursing.

[FR Doc. 88-16569 Filed 7-20-88; 8:45 a.m.]

BILLING CODE 4150-04-M

Centers for Disease Control

Gynecologic Cytology Quality Control Measures; Second Conference

ACTION: Notice of meeting—Second Conference on Quality Control Measures in Gynecologic Cytology.

Time and Date: 8:00 a.m. through 5:00 p.m., Thursday, September 1, 1988.

Place: Centers for Disease Control, Auditorium B, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

Status: Open to the public for participation, comment, and observation, limited only by space available.

Purpose: The conference will provide one session for professional organizations, Government agencies, and academic and clinical laboratories concerned with gynecologic cytology testing to present their recommendations for personnel standards, daily workload, external monitoring of laboratory performance, and intra-laboratory quality assurance programs. Additional sessions at the conference will discuss optimal specimen collection techniques, criteria for assessing the adequacy of a Pap smear, and comparability of the various diagnostic nomenclatures.

Contact person for more information: Vernon N. Houk, M.D., Director, Center for Environmental Health and Injury Control, CDC, Atlanta, Georgia 30333. Telephones: FTS: 236-4111; Commercial: (404) 488-4111.

Dated: July 14, 1988.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 88-16442 Filed 7-20-88; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

[Docket No. 88F-0209]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2-(8-heptadecenyl)-4, 5-dihydro-1*H*-imidazole-1-ethanol as a multipurpose additive for lubricants with incidental food contact.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and

Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204 202–472–5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8B4093) has been filed by Ciba-Geigy Corp., Three Skyline Dr., Hawthorne, NY 10532, proposing that § 178.3570 *Lubricants with incidental food contact* (21 CFR 178.3570) be amended to provide for the safe use of 2-(8-heptadecenyl)-4,5-dihydro-1*H*-imidazole-1-ethanol as a multipurpose additive for lubricants with incidental food contact.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: July 13, 1988.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 88–16378 Filed 7–20–88; 8:45 am]

BILLING CODE 4160–01–M

[FDA 225–88–4000]

Memorandum of Understanding Among the Food and Drug Administration, the Environmental Protection Agency, and the United Kingdom Department of Health and Social Security

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) among FDA, the Office of Pesticides and Toxic Substances, United States Environmental Protection Agency, and the Medical Division of Toxicology and Environmental Protection, United Kingdom Department of Health and Social Security. This MOU provides for (a) reciprocal recognition of each country's good laboratory practice program, (b) acceptance of test data collected in either country for evaluation of safety, and (c) implementation of procedures for continuing efforts between the countries.

DATE: The agreement became effective March 28, 1988.

FOR FURTHER INFORMATION CONTACT: Walter J. Kustka, Intergovernmental and Industry Affairs Staff (HFC–50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1583.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all agreements and memoranda of understanding between FDA and others shall be published in the **Federal Register**, the agency is publishing this memorandum of understanding.

Dated: July 14, 1988.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

Memorandum of Understanding Among the Food and Drug Administration, United States Department of Health and Human Services and the Office of Pesticides and Toxic Substances, United States Environmental Protection Agency and the Medical Division of Toxicology and Environmental Protection United Kingdom Department of Health and Social Security

I. Purpose

The participating agencies of the United States (US) and the United Kingdom (UK) have a concern for assuring the quality and integrity of safety evaluation data that support the approval of applications for research and/or marketing permits and licensing or registration of chemicals for agricultural, industrial, pharmaceutical, or food use. The parties share the view that health and environmental safety studies which are required to be submitted to a national authority should be conducted in accordance with principles of good laboratory practice (GLP) that are internationally recognized and that laboratories conducting such tests should be monitored by effective national inspection programs. Accordingly, this agreement provides for (a) reciprocal recognition of each country's good laboratory practice program (b) acceptance of test data collected in either country for evaluation of safety, and (c) implementation of procedures for continuing efforts between the countries.

It is intended that as a routine matter, inspections of health and environmental testing laboratories are to be carried out by the respective national authorities.

II. Background

Safety evaluation data submitted to one national authority are frequently based on studies conducted by laboratories located in another country. Therefore, the standards observed by those laboratories that conduct health and environmental safety studies which are submitted to the authorities of the other country should be conducted in accordance with principles of good laboratory practice that are internationally recognized. When the safety evaluation data submitted to a national authority originate from a laboratory within another country, the national authority of the country of origin should be able to provide the other with information that assures that the laboratory is operated in accordance with recognized good laboratory practices.

The GLP authorities in both the United States and the United Kingdom have established national programs of inspection to verify the compliance of laboratories with those standards. Both standards and inspection programs are in accord with the Decision of the Council of the Organization for Economic Cooperation and Development (OECD) on "The Mutual Acceptance of Data in the Assessment of Chemicals" (May 12, 1981) including Annex 2, "OECD Principles of Good Laboratory Practice." These standards and procedures are consistent with the July 26, 1983, recommendation of the OECD Council on "The Mutual Recognition of Compliance with Good Laboratory Practice."

A. Good Laboratory Practice

The participating agencies of the United States and the United Kingdom have published comparable standards of good laboratory practice relating to health and environmental studies for safety evaluation experiments.

The inspectors of the US Food and Drug Administration (FDA) will rely on regulations relating to Good Laboratory Practice for Nonclinical Laboratory Studies (21 CFR Part 58) in evaluating the laboratories and auditing the data from the studies conducted in the US.

The inspectors of the US Environmental Protection Agency (EPA) will rely on the regulations relating to Pesticide Programs, Good Laboratory Practice Standards (40 CFR Part 160) and Toxic Substances Control, Good Laboratory Practice Standards (40 CFR Part 792) in evaluating the laboratories and auditing the data from the studies conducted in the US.

The inspectors of the UK Department of Health and Social Security (DHSS) will rely on the Approved Code of Practice: Principles of Good Laboratory Practice made under the "Health and Safety: Notification of New Substances Regulations, 1982," in evaluating the